|1.||Lee, Jeong Min: 5 articles (01/2016 - 10/2013)|
|2.||Choi, Byung Ihn: 4 articles (01/2016 - 10/2013)|
|3.||Han, Joon Koo: 4 articles (01/2016 - 10/2013)|
|4.||Joo, Ijin: 3 articles (01/2016 - 01/2014)|
|5.||Park, Jisuk: 2 articles (04/2014 - 10/2013)|
|6.||Kim, Kyung Won: 2 articles (04/2014 - 10/2013)|
|7.||Kim, Soo Jin: 2 articles (04/2014 - 09/2010)|
|8.||Kim, Dal-Hyun: 2 articles (04/2014 - 09/2010)|
|9.||Grimm, Robert: 1 article (01/2016)|
|10.||Min, Young Joo: 1 article (06/2014)|
08/01/2014 - "Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors."
01/01/2014 - "Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors."
06/01/2014 - "The study assessed CKD-516 as a vascular disrupting agent or anti-cancer drug. "
01/01/2016 - "Materials and Methods With institutional Animal Care and Use Committee approval, 21 VX2 liver tumor-bearing rabbits (treated, n = 15; control, n = 6) underwent IVIM DW imaging with 12 b values (0-800 sec/mm(2)) and dynamic contrast-enhanced MR imaging performed before (baseline) CKD-516 administration and 4 hours, 24 hours, and 7 days after administration. "
08/01/2014 - "The apparent diffusion coefficient (ADC), true diffusion coefficient (D), pseudodiffusion coefficient (D*), perfusion fraction (f), and blood flow-related parameter (fD*) of tumors at different time points (baseline, 4 hours, 24 hours, 3 days, and 7 days after CKD-516 administration) were compared within the treated group (n = 15) by using the Friedman test as well as between the control (n = 6) and treated groups by using the Mann-Whitney test. "
|2.||Hepatocellular Carcinoma (Hepatoma)
04/01/2014 - "To evaluate the anticancer efficacy of CKD-516, a novel vascular-disrupting agent, alone and in combination with doxorubicin in the treatment of hepatocellular carcinoma (HCC). "
04/01/2014 - "Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model."
04/01/2014 - "Tumors from the combination group showed more extensive central and peripheral necrosis, with smaller viable peripheral layers than the CKD-516 group. "
06/01/2014 - "Extensive central necrosis of tumors was evident by 12 h after treatment with CKD-516 (2.5 mg/kg, i.p.). "
10/01/2013 - "In summary, CKD-516 is an effective VDA which results in rapid vascular shutdown by targeting the tubulin component of tumor vessels and thus leads to necrosis."
|3.||contrast agent BR1
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)